中文摘要：

目的：探讨急性淋巴细胞白血病（ALL）患者骨髓标本中小泛素样修饰蛋白特异性蛋白酶1（SENP1）和c-myb蛋白表达及其相关性，为阐明SENP1和c-myb在ALL中的作用、机制及与预后的关系提供依据。方法选取经确诊的ALL患者31例（ALL组，其中含B-ALL 22例，T-ALL 1例，未分类ALL 8例），将其分为低/中危组（n＝6）和高危组（n＝25）；另选取同期经形态学确诊的增生性骨髓象、增生性贫血患者31例作为对照组。采用real-time PCR及免疫细胞化学染色（SP法）检测SENP1、c-myb在ALL及对照组骨髓标本中mRNA及蛋白表达。结果 ALL患者骨髓标本及骨髓涂片中SENP1、c-myb均高表达，与对照组患者比较，差异有统计学意义（P＜0．05），Pearson相关性分析发现，SENP1与c-myb高表达具有相关性。SENP1、c-myb的表达在低/中危组低于高危组，但差异无统计学意义（P＞0．05）。结论 ALL患者骨髓标本中存在着SENP1、c-myb的高表达， SENP1与c-myb可能与ALL的发生、发展相关；但在不同危险度分级ALL患者中尚不能证明SENP1与c-myb表达有差异。

英文摘要：

Objective To investigate the SENP1 and c-myb gene expression and their correlations in bone marrow specimens in the patients with acute lymphoblastic leukemia （ALL ） to provide the basis for expounding the role ,mechanism and prognosis of SENP1 and c-myb in ALL .Methods 31 patients diagnosed with ALL （22 cases of B-ALL ,1 case of T-ALL and 8 cases of uncate-gorized ALL ;6 cases in the low/medium risk group ,25 cases in the high risk group） and 31 patients with proliferative bone marrow and hyperplastic anemia diagnosed by the morphology were taken as the control group .The real-time PCR and immunocytochemical staining（SP method） were adopted to detect the mRNA and protein expressions of SENP1 and c-myb in the bone marrow specimens of the ALL patients and the control group .Results The expression of SENP1 and c-myb were both increased in the bone marrow specimens and smears of ALL patients ,which showed the statistical difference compared with the control group （P＆lt; 0 .05） ,the Pearson correlation analysis found that the high expression of SENP1 and c-myb had correlation .The expression of SENP1and c-myb in the low/medium risk group were lower than that in the high risk group ,but the difference had no statistical significance . Conclusion The high expression of SENP1 and c-myb exists in the bone marrow specimens of the ALL patients ,SENP1 and c-myb could possibly have the correlation with the occurrence and development of ALL ;but now the differences of SENP1 and c-myb ex-pression among different risk groups of ALL patients are yet to be proven .